4Suppliers
8Customers
3Debt Items
20Related Chains

Lunai Bioworks Inc. Suppliers

TickerNameConfidenceEvidence
ONCOTELIC ONCOTELIC 90% The Series B Preferred Stock was allocated five (5) shares to Oncotelic (representing 62.5% of the Series B Preferred Stock and an aggregate Stated Value of $12,500,000)
PELERIN PELERIN 90% The Series B Preferred Stock was allocated three (3) shares to Pelerin (representing 37.5% of the Series B Preferred Stock and an aggregate Stated Value of $7,500,000)
ORANY ORANY 72% ow Renovaro Cube to control the sample preparation and medical device, thereby enabling faster commercialization analysis and quality control; and ● Expand its team to include biomedical scientists, …
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from LNAI graph: ow Renovaro Cube to control the sample preparation and medical device, thereby enabling faster commercialization ana…

Lunai Bioworks Inc. Customers

TickerNameConfidenceEvidence
CLEMANN-GROUP CLEMANN-GROUP 92% The Transaction is structured as a $20.0 million strategic investment in the Company in the form of Series B Convertible Preferred Stock
KAPOOSE-CREEK-BIO KAPOOSE-CREEK-BIO 92% During the three months ended March 31, 2026, the Company, through its wholly owned subsidiary BioSymetrics Corporation (Canada), entered into a research services agreement with Kapoose Creek Bio (th…
ORANY ORANY 72% ow Renovaro Cube to control the sample preparation and medical device, thereby enabling faster commercialization analysis and quality control; and ● Expand its team to include biomedical scientists, …
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from LNAI graph: ow Renovaro Cube to control the sample preparation and medical device, thereby enabling faster commercialization ana…
ASSOCIATES-LLC ASSOCIATES-LLC 62% extent of effort when performing audit procedures to evaluate the reasonableness of such estimates and assumptions. Our audit procedures related to the following: ● In relation to the GediCube goodwi…
GEDICUBE-INTL-LTD GEDICUBE-INTL-LTD 62% extent of effort when performing audit procedures to evaluate the reasonableness of such estimates and assumptions. Our audit procedures related to the following: ● In relation to the GediCube goodwi…
PLAZA-MEDICAL-OFFICE-BUILDING-LLC PLAZA-MEDICAL-OFFICE-BUILDING-LLC 62% e Agreement On June 20, 2022, the Company entered into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet of space currently rented b…
RENOVARO-CUBE-INTL-LTD RENOVARO-CUBE-INTL-LTD 62% have the same effect, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or any other governmental laws or regulations that apply, they may be su…

Lunai Bioworks Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
LNAI-DEBT-10738 Warrants outstanding: 3425399 90% xbrl warrant detail from xbrl 2024-06-30.
LNAI-DEBT Debt stack $2.8M 90% Market cache reports total debt of $2.8M.
LNAI-DEBT-10739 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.

Lunai Bioworks Inc. Acquisitions

Acquired EntityNameConfidenceEvidence
LNAI-ACQ-0001731122-26-000502 The Company entered into a binding agreement to acquire technology through a $20 million strateg... 85% The Company entered into a binding agreement to acquire technology through a $20 million strategic investment in the form of Series B Convertible Preferred Stock.

Lunai Bioworks Inc. Ownership

HolderNameConfidenceEvidence
LNAI-OWNER-NORTHERN-TRUST-CORPORATION Northern Trust Corporation 95% 13F/ownership overlay lists Northern Trust Corporation; shares held 37,402; ownership 0.15%; value $15,439; as of 2025-12-31.
LNAI-OWNER-VANGUARD-GROUP-INC Vanguard Group Inc 95% 13F/ownership overlay lists Vanguard Group Inc; shares held 497,011; ownership 2.05%; value $205,166; as of 2025-12-31.
LNAI-OWNER-STATE-STREET-CORPORATION State Street Corporation 95% 13F/ownership overlay lists State Street Corporation; shares held 35,728; ownership 0.15%; value $14,748; as of 2025-12-31.
LNAI-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC Geode Capital Management, LLC 95% 13F/ownership overlay lists Geode Capital Management, LLC; shares held 131,015; ownership 0.54%; value $54,082; as of 2025-12-31.
LNAI-OWNER-BLACKROCK-INC Blackrock Inc. 95% 13F/ownership overlay lists Blackrock Inc.; shares held 127,314; ownership 0.53%; value $52,555; as of 2025-12-31.
LNAI-OWNER-NINE-MASTS-CAPITAL-LTD Nine Masts Capital Ltd. 95% 13F/ownership overlay lists Nine Masts Capital Ltd.; shares held 24,220; ownership 0.10%; value $9,998; as of 2025-12-31.
LNAI-OWNER-CITADEL-ADVISORS-LLC Citadel Advisors Llc 95% 13F/ownership overlay lists Citadel Advisors Llc; shares held 20,632; ownership 0.09%; value $8,516; as of 2025-12-31.
LNAI-OWNER-UBS-GROUP-AG UBS Group AG 95% 13F/ownership overlay lists UBS Group AG; shares held 17,940; ownership 0.07%; value $7,405; as of 2025-12-31.
LNAI-OWNER-JANE-STREET-GROUP-LLC Jane Street Group, LLC 95% 13F/ownership overlay lists Jane Street Group, LLC; shares held 11,900; ownership 0.05%; value $4,912; as of 2025-12-31.
LNAI-OWNER-MILLENNIUM-MANAGEMENT-LLC Millennium Management Llc 95% 13F/ownership overlay lists Millennium Management Llc; shares held 166,744; ownership 0.69%; value $68,831; as of 2025-12-31.

Lunai Bioworks Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ORANY ORANGE 100.00 1 ['customer', 'supplier']
AMZE Amaze Holdings, Inc. 50.00 2
DWTX Dogwood Therapeutics, Inc. 50.00 2
CPRX Catalyst Pharmaceuticals, Inc. 50.00 2
AYTU Aytu BioPharma, Inc. 50.00 2
D Dominion Energy, Inc. 50.00 2
DARE Daré Bioscience, Inc. 50.00 2
CANF Can-Fite BioPharma Ltd. 50.00 2
DFTX Definium Therapeutics, Inc. 50.00 2
CHUC Charlie's Holdings, Inc. 50.00 2
CLNE Clean Energy Fuels Corp. 50.00 2
FENC Fennec Pharmaceuticals Inc. 50.00 2
EQR Equity Residential 50.00 2
CNOB ConnectOne Bancorp, Inc. 50.00 2
CYCN Cyclerion Therapeutics, Inc. 50.00 2
ESS Essex Property Trust, Inc. 50.00 2
ED Consolidated Edison, Inc. 50.00 2
SCNX Scienture Holdings, Inc. 50.00 2
CORT Corcept Therapeutics Incorporated 50.00 2
BLTE Belite Bio, Inc 50.00 2